Science 37 Holdings, Inc.

NasdaqCM:SNCE Rapport sur les actions

Capitalisation boursière : US$34.7m

This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !

Science 37 Holdings Gestion

Gestion contrôle des critères 2/4

Science 37 Holdings' CEO is Dave Coman, appointed in Nov 2019, has a tenure of 4.33 years. total yearly compensation is $8.06M, comprised of 6.8% salary and 93.2% bonuses, including company stock and options. directly owns 0.89% of the company’s shares, worth $309.55K. The average tenure of the management team and the board of directors is 3.3 years and 2.4 years respectively.

Informations clés

Dave Coman

Directeur général

US$8.1m

Rémunération totale

Pourcentage du salaire du PDG6.8%
Durée du mandat du directeur général4.3yrs
Propriété du PDG0.9%
Durée moyenne d'occupation des postes de direction3.3yrs
Durée moyenne du mandat des membres du conseil d'administration2.4yrs

Mises à jour récentes de la gestion

Recent updates

Science 37 Holdings, Inc. (NASDAQ:SNCE) Might Not Be As Mispriced As It Looks

Dec 18
Science 37 Holdings, Inc. (NASDAQ:SNCE) Might Not Be As Mispriced As It Looks

Investors Continue Waiting On Sidelines For Science 37 Holdings, Inc. (NASDAQ:SNCE)

Apr 17
Investors Continue Waiting On Sidelines For Science 37 Holdings, Inc. (NASDAQ:SNCE)

Science 37, Syapse team for faster patient enrollment in cancer trials

Aug 18

Science 37 reports Q2 mixed earnings; narrows FY22 guidance

Aug 11

Results: Science 37 Holdings, Inc. Exceeded Expectations And The Consensus Has Updated Its Estimates

May 13
Results: Science 37 Holdings, Inc. Exceeded Expectations And The Consensus Has Updated Its Estimates

Science 37 Holdings (NASDAQ:SNCE) Is In A Good Position To Deliver On Growth Plans

Apr 11
Science 37 Holdings (NASDAQ:SNCE) Is In A Good Position To Deliver On Growth Plans

Science 37: Pioneering Decentralized Clinical Trials

Jan 02

We Think Science 37 Holdings (NASDAQ:SNCE) Can Afford To Drive Business Growth

Nov 04
We Think Science 37 Holdings (NASDAQ:SNCE) Can Afford To Drive Business Growth

Analyse de la rémunération des PDG

Comment la rémunération de Dave Coman a-t-elle évolué par rapport aux bénéfices de Science 37 Holdings?
DateRémunération totaleSalaireBénéfices de l'entreprise
Sep 30 2023n/an/a

-US$125m

Jun 30 2023n/an/a

-US$134m

Mar 31 2023n/an/a

-US$121m

Dec 31 2022US$8mUS$550k

-US$51m

Sep 30 2022n/an/a

-US$50m

Jun 30 2022n/an/a

-US$41m

Mar 31 2022n/an/a

-US$43m

Dec 31 2021US$8mUS$435k

-US$94m

Sep 30 2021n/an/a

-US$42m

Jun 30 2021n/an/a

-US$35m

Mar 31 2021n/an/a

-US$33m

Dec 31 2020US$1mUS$400k

-US$32m

Rémunération vs marché: Dave's total compensation ($USD8.06M) is above average for companies of similar size in the US market ($USD662.89K).

Rémunération et revenus: Dave's compensation has been consistent with company performance over the past year.


PDG

Dave Coman (53 yo)

4.3yrs

Titularisation

US$8,062,854

Compensation

Mr. David Coman, also known as Dave, has been Chief Executive Officer of Science 37 Holdings, Inc. (formerly known as Science 37, Inc.) since November 2019 and serves as its Director since October 2021. He...


Équipe de direction

NomPositionTitularisationCompensationPropriété
David Coman
CEO & Director4.3yrsUS$8.06m0.89%
$ 309.5k
Christine Pellizzari
Chief Legal & Human Resources Officer and Secretary2.7yrsUS$4.65m0.24%
$ 83.4k
Darcy Forman
Chief Delivery Officer4.2yrsUS$3.93m0.26%
$ 90.6k
Mike Zaranek
Chief Financial Officer3.9yrspas de données0.15%
$ 52.2k
Irena Lambridis
VP and Head of Quality Assurance & Complianceless than a yearpas de donnéespas de données
Margie Kooman
Vice President of Marketing & Communications3.8yrspas de donnéespas de données
Drew Bustos
Chief Strategy & Marketing Officerno datapas de donnéespas de données
Jonathan Cotliar
Chief Medical Officer4.8yrsUS$486.60k0.69%
$ 240.9k
Michael Shipton
Chief Commercial Officer1.5yrspas de données0.059%
$ 20.4k
Tyler Van Horn
VP of Corporate Strategy & Chief of Staff2.2yrspas de donnéespas de données
Erica Prowisor
Senior VP of Patient & Provider Networksless than a yearpas de donnéespas de données

3.3yrs

Durée moyenne de l'emploi

51.5yo

Âge moyen

Gestion expérimentée: SNCE's management team is considered experienced (3.3 years average tenure).


Membres du conseil d'administration

NomPositionTitularisationCompensationPropriété
David Coman
CEO & Director2.4yrsUS$8.06m0.89%
$ 309.5k
John Hubbard
Independent Director3.5yrsUS$180.00k0.034%
$ 11.8k
Robert Faulkner
Independent Chairman of the Board2.4yrsUS$215.00k0.034%
$ 11.8k
Paul von Autenried
Independent Director1.5yrsUS$93.33k0.038%
$ 13.2k
Bhooshitha De Silva
Independent Director2.4yrspas de donnéespas de données
Neil Tiwari
Independent Director2.4yrsUS$165.00k0.034%
$ 11.8k
Emily Rollins
Independent Director2.4yrsUS$185.00k0.034%
$ 11.8k

2.4yrs

Durée moyenne de l'emploi

53yo

Âge moyen

Conseil d'administration expérimenté: SNCE's board of directors are not considered experienced ( 2.4 years average tenure), which suggests a new board.